Matches in Wikidata for { <http://www.wikidata.org/entity/Q94352269> ?p ?o ?g. }
Showing items 1 to 52 of
52
with 100 items per page.
- Q94352269 description "wetenschappelijk artikel" @default.
- Q94352269 description "наукова стаття" @default.
- Q94352269 name "AT-16PHASE II STUDY OF TIVOZANIB, AN ORAL VEGFR INHIBITOR, IN PATIENTS WITH RECURRENT GLIOBLASTOMA" @default.
- Q94352269 name "AT-16PHASE II STUDY OF TIVOZANIB, AN ORAL VEGFR INHIBITOR, IN PATIENTS WITH RECURRENT GLIOBLASTOMA" @default.
- Q94352269 type Item @default.
- Q94352269 label "AT-16PHASE II STUDY OF TIVOZANIB, AN ORAL VEGFR INHIBITOR, IN PATIENTS WITH RECURRENT GLIOBLASTOMA" @default.
- Q94352269 label "AT-16PHASE II STUDY OF TIVOZANIB, AN ORAL VEGFR INHIBITOR, IN PATIENTS WITH RECURRENT GLIOBLASTOMA" @default.
- Q94352269 prefLabel "AT-16PHASE II STUDY OF TIVOZANIB, AN ORAL VEGFR INHIBITOR, IN PATIENTS WITH RECURRENT GLIOBLASTOMA" @default.
- Q94352269 prefLabel "AT-16PHASE II STUDY OF TIVOZANIB, AN ORAL VEGFR INHIBITOR, IN PATIENTS WITH RECURRENT GLIOBLASTOMA" @default.
- Q94352269 P1433 Q94352269-CEA33474-8A9C-4EC8-8BFC-42A48AA2DE7B @default.
- Q94352269 P1476 Q94352269-1CF72731-98BA-4D13-B41F-2E3F0B9926C8 @default.
- Q94352269 P2093 Q94352269-061C0764-05DD-479D-B162-49650E0E7069 @default.
- Q94352269 P2093 Q94352269-637637D3-AB1E-411D-9F54-DB5059313664 @default.
- Q94352269 P2093 Q94352269-707683AF-0E38-48CC-B383-085A67728478 @default.
- Q94352269 P2093 Q94352269-8531100B-BB5C-436B-8835-4E45EC24D10F @default.
- Q94352269 P2093 Q94352269-AF391A59-4B33-4A12-98A2-B425FB734EFC @default.
- Q94352269 P2093 Q94352269-B68C1BE8-0B41-453B-A5E5-C233F52E32C9 @default.
- Q94352269 P2093 Q94352269-E73B42B2-BC89-4B99-9E93-69BD06C07684 @default.
- Q94352269 P2093 Q94352269-FB8ED2C3-08A1-4832-92E4-A43E2E7CD676 @default.
- Q94352269 P304 Q94352269-2C936261-EBC3-46F9-B596-C0974B405669 @default.
- Q94352269 P31 Q94352269-F1A705BF-1561-4491-923A-3FBF9DEA66C4 @default.
- Q94352269 P356 Q94352269-3485E85A-E1AB-41BC-8456-BE89E1518530 @default.
- Q94352269 P433 Q94352269-0A62F511-6223-4111-8CE6-FF0515D5CF27 @default.
- Q94352269 P478 Q94352269-CD6F2574-F160-40F7-8FC3-919619EEB4A8 @default.
- Q94352269 P50 Q94352269-2A10CD01-480D-4967-A217-4109C8D7540C @default.
- Q94352269 P50 Q94352269-E7027D26-91EF-479A-8943-87B204990741 @default.
- Q94352269 P577 Q94352269-474FD8A3-4440-42C6-B16C-2BCAA8140EFC @default.
- Q94352269 P921 Q94352269-93DE8B03-649B-4EE8-A374-651DFC8B369F @default.
- Q94352269 P921 Q94352269-F604E2D3-2897-45C6-817B-55CE9B9C884A @default.
- Q94352269 P932 Q94352269-3561F5DA-E4C7-4F94-9BA0-CF078087E7AC @default.
- Q94352269 P356 NOU237.16 @default.
- Q94352269 P1433 Q15724471 @default.
- Q94352269 P1476 "AT-16PHASE II STUDY OF TIVOZANIB, AN ORAL VEGFR INHIBITOR, IN PATIENTS WITH RECURRENT GLIOBLASTOMA" @default.
- Q94352269 P2093 "Andrew Chi" @default.
- Q94352269 P2093 "Bruce Rosen" @default.
- Q94352269 P2093 "Elizabeth Gerstner" @default.
- Q94352269 P2093 "John Evans" @default.
- Q94352269 P2093 "Jorg Dietrich" @default.
- Q94352269 P2093 "Tracy Batchelor" @default.
- Q94352269 P2093 "Vyshak Chandra" @default.
- Q94352269 P2093 "Yangming Ou" @default.
- Q94352269 P304 "v11-v11" @default.
- Q94352269 P31 Q13442814 @default.
- Q94352269 P356 "10.1093/NEUONC/NOU237.16" @default.
- Q94352269 P433 "Suppl 5" @default.
- Q94352269 P478 "16" @default.
- Q94352269 P50 Q105531697 @default.
- Q94352269 P50 Q55459006 @default.
- Q94352269 P577 "2014-11-01T00:00:00Z" @default.
- Q94352269 P921 Q282142 @default.
- Q94352269 P921 Q7810457 @default.
- Q94352269 P932 "4217793" @default.